Goodwin has advised ATHAGORAS Group (“ATHAGORAS”), a portfolio company of GREENPEAK PARTNERS (“GREENPEAK”), on the financing of the acquisition of CSO Pharma Consulting (“CSO”) and MIGx AG ("MIGX").
CSO provides reliable services and professional support for pharmaceutical companies and healthcare providers in the fields of Pharmacovigilance, Medical Affairs, Quality Management & GDP as well as Development consulting. In addition, CSO offers an audited Pharmacovigilance system and processes essential for the wholesale license and as such serves as a dedicated outsourcing partner for its customers.
Founded in 2019 as a startup, MIGX has quickly established itself as a trusted technology partner in the Life Sciences sector. Specialising in solving complex data challenges and driving digital transformation, MIGX combines cutting-edge technology with deep industry expertise.
ATHAGORAS is building a group of leading service providers to create a tech-enabled European specialist service provider for the clinical and commercial development of healthcare innovations in the pharmaceutical & biotech industry within regulatory affairs, pharmacovigilance, as well as market access and real-world evidence.
GREENPEAK is a leading specialist focused on building and developing platforms that drive sustainable growth. With a hands-on approach, they collaborate closely with businesses to foster long-term value creation and success. By partnering with companies that share their vision and values, GREENPEAK creates synergistic ecosystems that fuel innovation and work toward a better future for all.
Goodwin’s transaction team was led by Munich partner Winfried M. Carli and included Frankfurt associates Rebecca Stöcklein and Marius Garnatz (Private Equity/Finance).